Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SITC 2021 | Safety and preliminary evidence for efficacy for propranolol + pembrolizumab in metastatic melanoma

Marc S. Ernstoff, MD, National Institutes of Health, Bethesda, MD, gives us an update on the results of a Phase I dose-escalation study evaluating the safety, tolerability and efficacy of propranolol hydrochloride plus pembrolizumab in locally advanced and metastatic melanoma (NCT03384836). The trial reported no dose-limiting toxicities and the recommended phase 2 dose was determined at 30 mg propranolol twice daily (BID). Common treatment-related adverse events included rash, fatigue and vitiligo in 44% of patients. Only one of nine patients developed two grade 3/4 adverse events. In addition, this combination showed promising efficacy, with an objective response rate (ORR) of 78%. There were no significant changes in treatment-associated biomarkers. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.